Latin-American Von Willebrand Disease Registry

Status Not yet recruiting

Clinical Trial Summary

Establish a Latin-American network of centers and professionals with the aim of:

- To register VWD patients in retrospective/prospective study, using a database, available online, common to all

- To register the bleeding history, the treatment and the events of VWD patients in the region

- To investigate the influence of VWD on quality of life

Clinical Trial Description

von Willebrand disease (VWD) is the most common autosomal bleeding disorder, mostly inherited as dominant trait. VWD is due to deficiency/abnormality of von Willebrand factor (VWF). The prevalence of VWD is unknown, but estimated as 0.1% to 1% of the general population. Although the autosomal inheritance pattern would suggest an equal distribution of male and female patients, the disease is diagnosed in more females because of female-specific hemostatic challenges: menses, ovulation, pregnancy and childbirth. Diagnosis of VWD is made by assessing personal and family history of bleeding, physical examination and completed with specific laboratory tests.

There is limited information on the epidemiology of VWD in developing countries. Some countries in Latin America have registries of severe disease that, although it is the rarest form, carries the highest costs for regional health systems. So that the prevalence of clinical symptoms and laboratory features of the disease as well as the management of the disease in Latin America is unknown.

The present project aims to establish a network of centers and professionals with the objective to register and investigate all patients with VWD in Latin America, using a database available online common to all, to gain understanding about phenotype, genotype and management of VWD in the region. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04279717
Study type	Observational [Patient Registry]
Source	Academia Nacional de Medicina
Contact	Analia Sanchez Luceros, PhD, MD
Phone	+5491152203235
Email	sanchezluceros@gmail.com
Status	Not yet recruiting
Phase
Start date	February 2020
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01651468` - The Effect of the Nutraceutical "Hemofix" on the Coagulation System	N/A
Active, not recruiting	`NCT00555555` - Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients	Phase 4
Terminated	`NCT00178542` - Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle	N/A
Completed	`NCT02552576` - Study of Voncento® in Subjects With Von Willebrand Disease	Phase 4
Recruiting	`NCT02869074` - Molecular and Clinical Profile of Von Willebrand Disease in Spain
Completed	`NCT01602419` - Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Completed	`NCT01224808` - Extension Study of Biostate in Subjects With Von Willebrand Disease	Phase 3
Completed	`NCT00805051` - Acquired Von Willebrand Syndrome in Severe Aortic Stenosis	N/A
Withdrawn	`NCT00694785` - A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B	Phase 2
Completed	`NCT00168090` - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)	Phase 4
Completed	`NCT02246881` - A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.	Phase 3
Completed	`NCT04657887` - Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Withdrawn	`NCT00630448` - Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)	N/A
Terminated	`NCT00387192` - A Study With OPTIVATE® in People With Von Willebrand Disease	Phase 3
Completed	`NCT02973087` - rVWF IN PROPHYLAXIS	Phase 3
Completed	`NCT01410227` - Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)	Phase 3
Completed	`NCT01949220` - Willebrand International Non-interventional Global Surveillance
Completed	`NCT01589848` - Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador	N/A
Completed	`NCT00941616` - Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease	Phase 2/Phase 3
Completed	`NCT00557908` - The Von Willebrand Disease (VWD) International Prophylaxis Study	N/A